glp 1 trends GLP-1 Antagonists Increase Plan Drug Spend - What's Next Monitoring Report: GLP-1 RA Prescribing

3 The Lancet Phase 1b combination trialEnebo LB et al

Furthermore, in another meta-analysis [23], which excluded ELIXA [24] due to fact that lixisenatide is a short-acting GLP-1RA and all participants had acute coronary syndrome, GLP-1RAs were associated with significant reductions in MACE (HR 0.85, 95% CI 0.800.90), cardiovascular death (HR 0.85, 95% CI 0.780.93), stroke (HR 0.81, 95% CI 0.740.90), and myocardial infarction (HR 0.88, 95% CI 0.810.96) (Table 2)

Some plans cover Ozempic for diabetes but not Wegovy for weight loss, even though both contain semaglutide

Lu X, Xu X, Ding Y, Gong X, Ming L, Dai X, et al